WASHINGTON, June 29, 2026 /PRNewswire/ -- The Danaher Foundation, supported by Danaher Corporation (

Dan Deming talks joins today's Big 3 and highlights JPMorgan Chase (JPM) as shares touch new record

Danaher (DHR) is looking like an interesting pick from a technical perspective, as the company reach

Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and othe

Wall Street analysts changed outlook on top names like MKTX, PRCT, VOD, and JILL. See ratings page a

Wall Street analysts change outlook for top stocks. See upgrades, downgrades, and initiations on ana

Top Wall Street analysts change outlook on top names. See analyst ratings page for changes, includin

Piper Sandler analyst David Westenberg initiates coverage on Danaher (NYSE:DHR) with a Neutral ra

Jim Cramer says investors are aggressively favoring AI stocks while heavily punishing companies that

Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global innovator in patient monitorin

Morgan Stanley analyst Kallum Titchmarsh maintains Danaher (NYSE:DHR) with a Overweight and lower

Wells Fargo analyst Brandon Couillard maintains Danaher (NYSE:DHR) with a Equal-Weight and lowers

Guggenheim analyst Subbu Nambi maintains Danaher (NYSE:DHR) with a Buy and lowers the price targe

Danaher Q1 earnings beat estimates as bioprocessing drives growth, while diagnostics weakens, and th

For full year 2026, the Company continues to expect that non-GAAP core revenue will increase in the

Baird analyst Catherine Schulte maintains Danaher (NYSE:DHR) with a Outperform and lowers the pri

Goldman Sachs analyst Evie Koslosky maintains Danaher (NYSE:DHR) with a Buy and lowers the price

Trump, in January, said "inflation has been defeated." Wall Street is now bracing for a 0.9%

Evercore ISI Group analyst Vijay Kumar maintains Danaher (NYSE:DHR) with a Outperform and lowers

Danaher's acquisition of Masimo shows promising financial upside and long-term growth potential

The Transaction is subject to the satisfaction or waiver of certain closing conditions, including th

https://www.wsj.com/business/deals/danaher-strikes-10-billion-deal-for-masimo-1bd50e57?mod=business_

Danaher approaches a $9.9 billion acquisition of Masimo following activist-led board changes and rec

Revvity beat Q4 earnings and revenue estimates, driven by diagnostics growth, and forecast higher 20

Wall Street posted modest gains on Wednesday, while gold extended its relentless rally, shattering r

Danaher beat Q4 sales and earnings estimates, showed strength in bioprocessing and diagnostics, and

Danaher (NYSE:DHR) reported quarterly earnings of $2.23 per share which beat the analyst consensus e

Earnings season is in full-swing with reports this week from several Mag Seven names, big tech compa

TD Cowen analyst Dan Brennan maintains Danaher (NYSE:DHR) with a Buy and raises the price target

Guggenheim analyst Subbu Nambi maintains Danaher (NYSE:DHR) with a Buy and raises the price targe

Wells Fargo analyst Brandon Couillard maintains Danaher (NYSE:DHR) with a Equal-Weight and raises

Goldman Sachs analyst Evie Koslosky initiates coverage on Danaher (NYSE:DHR) with a Buy rating an

Morgan Stanley analyst Kallum Titchmarsh initiates coverage on Danaher (NYSE:DHR) with a Overweig